Meeting
2018 ASCO Annual Meeting
Clinical development of asciminib (ABL001) in chronic myeloid leukemia (CML): A randomized phase 3 study vs. bosutinib.
Authors
Michael J. Mauro
Memorial Sloan Kettering Cancer Center, New York, NY
Michael J. Mauro , Fabian Lang , Dong-Wook Kim , Jorge E. Cortes , Timothy P. Hughes , Andreas Hochhaus , Hironobu Minami , Carla Boquimpani , Yosuke Minami , Daniel J. DeAngelo , Massimo Breccia , Moshe Talpaz , Yeow-Tee Goh , Oliver Ottmann , Manu Sondhi , Stephan Hois , Véronique Bédoucha , Shu-Fang Hsu Schmitz , Delphine Rea
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Chronic Leukemia—CML
Clinical Trial Registration Number
NCT03106779
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS7081)
DOI
10.1200/JCO.2018.36.15_suppl.TPS7081
Abstract #
TPS7081
Poster Bd #
137a
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
A multicenter, randomized phase III study of asciminib (ABL001) versus bosutinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 tyrosine kinase inhibitors (TKIs).
First Author: Michael J. Mauro
Poster
2023 ASCO Annual Meeting
ASC2ESCALATE: A US phase 2, single-arm, dose-escalation study of asciminib monotherapy in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with 1 prior tyrosine kinase inhibitor (TKI).
First Author: Ehab L. Atallah
Poster
2023 ASCO Annual Meeting
Report of a chronic myeloid leukemia registry in a low-and middle-income setting.
First Author: Nicolas Anthony Othieno-Abinya
Poster
2019 ASCO Annual Meeting
Phase 3 PhALLCON study: Ponatinib (PON) versus imatinib (IM) with reduced-intensity chemotherapy (CT) in patients (pts) with newly diagnosed Philadelphia chromosome–positive (Ph+) ALL.
First Author: Elias Jabbour